Ono Pharmaceutical (OTCMKTS:OPHLY – Get Free Report) will likely be issuing its resultson Friday, July 31st. Analysts expect Ono Pharmaceutical to post earnings of $0.0716 per share and revenue of $685.0340 million for the quarter.
Ono Pharmaceutical Trading Down 1.0%
Shares of Ono Pharmaceutical stock opened at $4.89 on Wednesday. Ono Pharmaceutical has a twelve month low of $3.55 and a twelve month high of $5.75. The company has a 50-day simple moving average of $4.83 and a two-hundred day simple moving average of $5.01.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Read More
- Five stocks we like better than Ono Pharmaceutical
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
